EDIT250117P1000
- 0.05
- 0.000.00%
Editas Medicine Newsroom
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
Clear Street Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $4
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Cuts Target Price to $5
Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5
JP Morgan Downgrades Editas Medicine to Underweight
J.P. Morgan Downgrades Editas Medicine(EDIT.US) to Sell Rating
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
Express News | Editas Medicine Inc : JP Morgan Cuts to Underweight From Neutral
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $3
Editas Medicine Price Target Lowered to $8 From $10 at Baird
Editas Medicine Reshapes Future With In Vivo Focus Amid Major Workforce Cuts
Editas Medicine Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4
Editas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial Challenges
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Express News | Editas Medicine Shares Are Trading Lower After Stifel and Chardan Capital Downgraded the Stock and Multiple Firms Cut Their Respective Price Targets
Express News | Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $3